Liposomal irinotecan combo for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer or cancer of the gastroesophageal junction (where the stomach meets the esophagus).
- You have tried at least one prior treatment that no longer works or you cannot tolerate.
- You are 18 years or older.
- Your doctor expects you to live at least 3 more months.
- You have a tumor that can be measured on a CT scan (at least 1 cm in size).
- Your kidney, liver, and blood cell counts meet certain safety levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a combination of liposomal irinotecan and albumin-bound paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line chemotherapy. It may be an option if you have already tried a fluorouracil-based treatment.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.